About Us
JanusQ is developing treatments for neurological diseases by targeting mitochondrial dysfunction.
Small-Peptide Pharmaceuticals
JanusQ is an early-stage company developing peptide-based therapies that target mitochondrial dysfunction in neurodegenerative diseases. With two lead peptides showing strong efficacy in animal models of Alzheimer’s and Huntington’s Diseases (AD and HD), we are well positioned to drive towards the clinic in pursuit of treatments for these debilitating and, ultimately, fatal diseases.
Mitochondrial Dysfunction
Therapies focused on hypothesized causative agents of AD and HD have not seen clinical success, emphasizing the urgent need for alternative approaches that address early molecular events in AD and HD pathogenesis. We recognized that a common thread in many early neurodegeneration etiologies is mitochondrial dysfunction, which accelerates disease progression and cognitive decline. Our approach is to use a peptide-based strategy that targets proteins that play major roles in stabilizing and promoting the normal physiology of mitochondria.